Jones D L, Weiss S M, Malow R, Ishii M, Devieux J, Stanley H, Cassells A, Tobin J N, Brondolo E, LaPerriere A, Efantis-Potter J, O'Sullivan M J, Schneiderman N
The University of Miami School of Medicine, Miami, Florida 33136, USA.
J Urban Health. 2001 Dec;78(4):593-604. doi: 10.1093/jurban/78.4.593.
Interventions aimed at reducing sexual transmission of human immunodeficiency virus/sexually transmitted diseases (HIV/STDs) have focused primarily on male condom use among seronegative men and women. However, female-controlled sexual barriers (female condoms and vaginal microbicides) offer women living with acquired immunodeficiency syndrome (AIDS) alternative methods to protect themselves and others from disease transmission. A pilot behavioral intervention was conducted to increase sexual barrier use and enhance and assess factors related to acceptability. Participants (N = 178) were drawn from the Stress Management and Relaxation Training with Expressive Supportive Therapy (SMART/EST) Women's Project, a multisite phase III clinical trial for women living with AIDS (Miami, FL; New York City, NY; Newark, NJ). Intervention participants (n = 89) were matched for age and ethnicity with control condition participants (n = 89). Women were African American (52%), Haitian (15%), Hispanic (19%), Caucasian (10%), and other ethnicities (4%). The intervention condition received barrier products (male and female condoms and spermicides based on nonoxynol-9 in the form of vaginal gel, film, and suppositories) during three sessions held over 3 months. Data on barrier use and acceptability were analyzed at baseline and 3 and 9 months postintervention. Use of N-9 spermicides on a trial basis increased significantly by 3 months in the intervention conditions (22%-51%, P <.05). Cultural differences in acceptability were greatest between Haitian women and women in other ethnic groups. Exposure to this pilot behavioral intervention was associated with increased acceptability and use of chemical barriers without decreased use of male condoms.
旨在减少人类免疫缺陷病毒/性传播疾病(HIV/STD)性传播的干预措施主要集中在血清反应阴性的男性和女性使用男用避孕套上。然而,女性控制的性屏障(女用避孕套和阴道杀菌剂)为获得性免疫缺陷综合征(AIDS)患者提供了保护自己和他人免受疾病传播的替代方法。开展了一项试点行为干预,以增加性屏障的使用,并增强和评估与可接受性相关的因素。参与者(N = 178)来自压力管理与放松训练及表达性支持疗法(SMART/EST)女性项目,这是一项针对艾滋病女性患者的多中心III期临床试验(佛罗里达州迈阿密;纽约市;新泽西州纽瓦克)。干预组参与者(n = 89)在年龄和种族上与对照组参与者(n = 89)相匹配。女性参与者中,非裔美国人占52%,海地人占15%,西班牙裔占19%,白种人占10%,其他种族占4%。干预组在为期3个月的三次会议期间获得了屏障产品(男用和女用避孕套以及基于壬苯醇醚-9的阴道凝胶、薄膜和栓剂形式的杀精剂)。在基线以及干预后3个月和9个月分析了屏障使用和可接受性的数据。在干预组中,试验性使用N-9杀精剂在3个月时显著增加(从22%增至51%,P <.05)。海地女性与其他种族女性在可接受性方面的文化差异最大。参与这项试点行为干预与化学屏障的可接受性和使用增加相关,且男用避孕套的使用并未减少。